RNA therapy targets hard-to-reach bone marrow cancer cells
- What role do Macrophages play in Tumor Immunotherapy?
- Menstrual Cycle May Affect Insulin Sensitivity
- Infection with Monkeypox Virus Induces Natural Immunity to Prevent Re-Infection
- Painkillers and Contraceptives: Risky Combination for Women
- IAEA Shutdown Soon Due to Japan Nuclear Water and Australia Submarines?
- Baby Crying Elicits Oxytocin Release in Mothers
RNA therapy targets hard-to-reach bone marrow cancer cells
- Nearly 300 People Food Poisoning in Japanese 130-Year Restaurant
- FDA’s First Potential TIL Therapy Review Delayed: How to Understand FDA’s “Resource Constraints”?
- A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million
- Nuclear contaminated water: Japanese government paid bribes and corrected the IAEA report
- Top 20 Companies of Instruments and Medical Equipment In The World
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- How long can the patient live after heart stent surgery?
RNA therapy targets hard-to-reach bone marrow cancer cells.
RNA therapy is emerging as a promising cancer treatment, but some types of cancer do not respond well to the therapy. Now, scientists at Tel Aviv University have demonstrated a way to treat multiple myeloma using RNA drugs.
Multiple myeloma is a cancer that affects a patient’s plasma cells. When these important immune cells become cancerous, they accumulate in the bone marrow, causing pain and immune problems. While the disease can be managed, there is currently no cure, mainly because it is difficult to get drugs to the tumors inside the patient’s bone.
In the new study, researchers in Tel Aviv demonstrate a promising new technique. It involves an RNA-based drug, part of an area of cancer-fighting that is beginning to gain traction. The drug’s active ingredient is a molecule called a small interfering RNA (siRNA), which inhibits the action of a target gene, preventing it from making a protein.
In this case, the RNA’s target gene is CKAP5, and without the corresponding protein, the cells can no longer divide. To ensure that this deadly effect only applies to cancer, the drug-carrying lipid nanoparticles are coated with antibodies that lock onto structures only on multiple myeloma cancer cells.
The Tel Aviv research team tested the technique on multiple myeloma cancer cells with several different structures. In a batch of lab-grown cells, the nanoparticles wiped out about 90 percent of the cells. They then tested the therapy on cancer cells from multiple myeloma patients, successfully eradicating 60 percent of the cancer cells. Finally, they injected the drug into mice with the disease, and as a result, about 66% of the cancer cells were eliminated, and the symptoms of the mice were also significantly improved.
While there is still much work to be done before it can be tested in humans, the team says these early results are promising.
“The drug delivery system we developed is the first to specifically target cancer cells within the bone marrow and the first to show that silencing Expression of the CKAP5 gene can be used in a system that kills blood cancer cells.
The research was published in the journal Advanced Science.
RNA therapy targets hard-to-reach bone marrow cancer cells.
(source:internet, reference only)
Disclaimer of medicaltrend.org
